BRCA2 and cancer: In view of the involvement of IDO in PARP-mediated DNA repair in cancer cells we hypothesized that concurrent downregulation of IDO and BRCA2 in cells would reduce PARP-mediated DNA repair and HRR, respectively, and sensitize cancer cells to olaparib more effectively than knockdown of either target alone.